Overview

Phase 2/3 Study of IGSC, 20% in PIDD

Status:
Completed

Trial end date:
2015-03-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Treatments:

Antibodies
gamma-Globulins
Immunoglobulin G
Immunoglobulins
Immunoglobulins, Intravenous
Pharmaceutical Solutions
Rho(D) Immune Globulin